Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 15/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.38 |
| ▸ | KIF5B | P33176 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828595 | 0.88 | EPHA2 (0.36) | EPHA2RETEGFRMAPK14KDR | |
| SCHEMBL5828594 | 0.88 | EPHA2 (0.36) | EPHA2RETEGFRMAPK14KDR | |
| SCHEMBL6981726 | 0.85 | EPHA2 (0.57) | EPHA2KDREPHB4 | |
| SCHEMBL5828868 | 0.85 | HTT (0.48) | RETEGFRMAPK14KDRKIF5B | |
| SCHEMBL5828872 | 0.85 | HTT (0.48) | RETEGFRMAPK14KDRKIF5B | |
| SCHEMBL6983822 | 0.82 | EPHA2 (0.42) | EPHA2RETEGFRMAPK14KDR | |
| SCHEMBL5828729 | 0.81 | EGFR (0.50) | RETEGFRMAPK14KDR | |
| SCHEMBL5828728 | 0.81 | EGFR (0.50) | RETEGFRMAPK14KDR | |
| SCHEMBL5827881 | 0.81 | RET (0.47) | RETEGFRKDRKIF5B | |
| SCHEMBL5827885 | 0.81 | RET (0.47) | RETEGFRKDRKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |